Key points
- The Precision Medicine Initiative defines precision medicine as an approach to disease treatment and prevention that accounts for individual variability in genes, environment, and lifestyle.
- In practice, it often means using a biomarker, such as a tumor mutation, to decide which patients should receive a drug.
- Imatinib for chronic myeloid leukemia, which targets the protein produced by a specific genetic abnormality, is one of the defining early examples.
- Drug programs that selected patients with biomarkers have had about double the overall likelihood of approval of programs that did not.
- Many targeted drugs require an FDA-approved companion diagnostic test to identify eligible patients.
For most of medical history, treatments have been designed for the average patient. A drug that helps 30% of people with a disease is given to everyone with that disease, and doctors find out afterward who responded. Precision medicine aims to identify those likely responders in advance.
The definition
According to the Precision Medicine Initiative, as quoted by the National Library of Medicine, precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person."
The term is often used interchangeably with personalized medicine. Precision medicine is generally preferred because the aim is not usually a treatment designed for one unique person. It is to sort patients into groups that respond differently, and to match each group with the right treatment.
How it works in practice
Most precision medicine today follows the same pattern:
- Identify a biological difference between patients that affects how a disease behaves or how a drug works, often a genetic mutation.
- Develop a drug that acts specifically on that difference.
- Develop a test, called a biomarker test or companion diagnostic, that identifies which patients have it.
- Give the drug to patients who test positive.
The defining example: imatinib
Chronic myeloid leukemia (CML) is driven by a genetic abnormality that fuses two genes, producing an abnormal, overactive enzyme called BCR-ABL. Imatinib was designed to block that enzyme.
In an early clinical trial reported in the New England Journal of Medicine in 2001, 53 of 54 patients treated with daily doses of 300 mg or more had complete hematologic responses, meaning their blood counts returned to normal. These were patients whose disease had not responded to earlier treatment. Imatinib showed that a drug designed around the specific molecular cause of a cancer could work dramatically better than conventional therapy, and it became a model for targeted drug development.
Precision medicine beyond cancer
| Area | How precision medicine is used |
|---|---|
| Cancer | Choosing targeted therapies based on tumor mutations or protein markers |
| Rare genetic diseases | Treatments designed for a specific faulty gene or mutation |
| Drug safety | Screening for genetic variants that predict serious side effects |
| Drug dosing | Adjusting doses for people who process a drug unusually fast or slowly, known as pharmacogenomics |
The FDA maintains a Table of Pharmacogenomic Biomarkers in Drug Labeling, which lists the approved drugs whose prescribing information mentions a genetic or other biomarker that can affect dosing, safety, or effectiveness.
Companion diagnostics
When a drug is only effective, or only safe, in patients with a particular biomarker, the FDA may require a companion diagnostic: a test that provides information essential for the drug's safe and effective use. The drug and the test are often reviewed in parallel, and the drug's label specifies that patients must be tested. The FDA publishes a list of cleared and approved companion diagnostic devices.
Why precision medicine improves development odds
Precision medicine changes the odds of drug development as well as treatment. A drug tested in a broad population may appear to fail because its benefit is concentrated in a subgroup and diluted by everyone else. Testing it only in the patients most likely to respond makes a real effect easier to detect.
In the 2021 BIO, Informa Pharma Intelligence, and QLS Advisors analysis of 2011–2020 programs, development programs that used patient preselection biomarkers had an overall likelihood of approval from Phase 1 of 15.9%, compared with 7.6% for programs that did not. See What Are the Chances of FDA Approval After Phase 2?
Challenges
- Smaller markets. Restricting a drug to a biomarker-defined group means fewer eligible patients.
- Testing access. Precision treatments only help if patients are tested, and testing is not available everywhere.
- Resistance. Tumors can acquire new mutations that make a targeted drug stop working, which is why many cancer patients eventually need further lines of treatment.
- Evidence gaps. Most genomic research has involved people of European ancestry, so biomarker findings may not apply equally to all populations.
- Not every disease has a clear biomarker. For many common conditions, no single test reliably predicts who will respond.
Precision medicine on Spectral Genomics
When an experimental drug targets a biomarker-defined population, its profile will identify the biomarker, whether a companion diagnostic exists or is in development, and how the biomarker was used in its clinical trials. These details are among the most important for understanding a drug's prospects.
Sources
- MedlinePlus Genetics (National Library of Medicine). What is precision medicine?Regulator
- Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031–1037.Peer-reviewed
- U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices.Regulator
- U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling.Regulator
- Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.